SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sahin Coban, Murat Kekilli, Seyfettin Köklü, Approach and Management of Patients with Chronic Hepatitis B and C During the Course of Inflammatory Bowel Disease, Inflammatory Bowel Diseases, 2014, 20, 11, 2142

    CrossRef

  2. 2
    Resat Ozaras, Bilgul Mete, Bahadir Ceylan, Nail Ozgunes, Alper Gunduz, Hayat Karaosmanoglu, Atahan Cagatay, Kadir Gokturk, Levent Erdem, Funda Kocak, Ebubekir Senates, Fehmi Tabak, First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment, European Journal of Gastroenterology & Hepatology, 2014, 26, 7, 774

    CrossRef

  3. 3
    T.-S. Huang, Y.-C. Shyu, H.-Y. Chen, S.-S. Yuan, J.-N. Shih, P.-J. Chen, A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma, Journal of Viral Hepatitis, 2013, 20, 10
  4. 4
    Wenpeng Li, Nadia Warner, Vitina Sozzi, Lilly Yuen, Danni Colledge, Tong Li, Hui Zhuang, Stephen Locarnini, Peter A. Revill, Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype, Hepatology International, 2013, 7, 2, 443

    CrossRef

  5. 5
    E. Cholongitas, G.V. Papatheodoridis, High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virus Recurrence After Liver Transplantation: A Systematic Review, American Journal of Transplantation, 2013, 13, 2
  6. 6
    Kristie Bloom, Abdullah Ely, Claudio Mussolino, Toni Cathomen, Patrick Arbuthnot, Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases, Molecular Therapy, 2013, 21, 10, 1889

    CrossRef

  7. 7
    Musa D. Marimani, Abdullah Ely, Maximilian C.R. Buff, Stefan Bernhardt, Joachim W. Engels, Patrick Arbuthnot, Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2′-O-guanidinopropyl modified siRNAs, Bioorganic & Medicinal Chemistry, 2013, 21, 20, 6145

    CrossRef

  8. You have free access to this content8
    T.-M. Chen, C.-C. Chang, P.-T. Huang, C.-F. Wen, C.-C. Lin, Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients, Alimentary Pharmacology & Therapeutics, 2013, 37, 2
  9. 9
    Michael P. Collins, William David Arnold, John T. Kissel, The Neuropathies of Vasculitis, Neurologic Clinics, 2013, 31, 2, 557

    CrossRef

  10. 10
    Pietro Vajro, Claudio Veropalumbo, Sergio Maddaluno, Mariacarolina Salerno, Giancarlo Parenti, Claudio Pignata, Treatment of children with chronic viral hepatitis: what is available and what is in store, World Journal of Pediatrics, 2013, 9, 3, 212

    CrossRef

  11. 11
    Stephanos J. Hadziyannis, Dimitrios Vassilopoulos, Emilia Hadziyannis, Antiviral Agents, 2013,

    CrossRef

  12. 12
    C.-Y. Peng, H.-C. Lai, Y.-F. Li, W.-P. Su, P.-H. Chuang, J.-T. Kao, Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2012, 35, 4
  13. 13
    Jessica P. Hwang, John M. Vierling, Andrew D. Zelenetz, Susan C. Lackey, Rohit Loomba, Hepatitis B virus management to prevent reactivation after chemotherapy: a review, Supportive Care in Cancer, 2012, 20, 11, 2999

    CrossRef

  14. 14
    R.M. Martín Mateos, F. García-Alonso, V. Moreira Vicente, Hepatitis crónica por virus B. Historia natural y tratamiento, Medicine - Programa de Formación Médica Continuada Acreditado, 2012, 11, 9, 521

    CrossRef

  15. 15
    F. Casals-Seoane, B. Arberas-Diez, R. Moreno-Otero, Letter: acute hepatitis B – to treat or not to treat?, Alimentary Pharmacology & Therapeutics, 2012, 36, 1
  16. 16
    Dimitrios Vassilopoulos, Leonard H. Calabrese, Management of rheumatic disease with comorbid HBV or HCV infection, Nature Reviews Rheumatology, 2012, 8, 6, 348

    CrossRef

  17. 17
    Stephanos J. Hadziyannis, Dimitrios Vassilopoulos, What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B, Current Hepatitis Reports, 2012, 11, 2, 65

    CrossRef